Sensitivity to CPT-11 and platinum derivatives of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses

概要

論文の詳細を見る
In this study, immunohistochemistry was used to detect Topo-1 and Bax/ERCC-1 expression in patients who had lymph node metastasis of stage II/III gastric cancer with occult neoplastic cells (ONCs) in their lymph node sinuses. In addition, tumor sensitivity was compared between CPT-11 and platinum agents. In the recurrence group (RG) (n=28), immunohistochemistry revealed high Topo-1 expression in 3 patients (10.7%) and low expression in 25 patients (89.3%), while there was high expression in 1 patient (11.1%) and low expression in 8 patients (88.9%) from the non-recurrence group (N-RG) (n=9) (Not significant; N.S.). Immunostaining showed high Bax/low ERCC-1 expression in 11 patients (39.3%) from the RG and other patterns of expression in 17 patients (60.7%), while high Bax/low ERCC-1 expression was observed in 3 patients (33.3%) from the N-RG and other patterns were noted in 6 patients (66.7%) (N.S.). There was a significant difference between the rate of high-Bax/low-ERCC-1 expression and high Topo-1 expression in the RG (p=0.0136). These results suggest that platinum derivatives such as CDDP are more effective than CPT-11 in both RG and N-RG of stage II/III gastric cancer with ONCs.
日本癌病態治療研究会の論文